Company Description
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
The company has a strategic collaboration agreement with Stryker Corporation for technology co-development.
Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Harel Gadot |
Contact Details
Address: 25 Recreation Park Dr Suite 108 Hingham, Massachusetts 02043 United States | |
| Phone | 908-938-5561 |
| Website | microbotmedical.com |
Stock Details
| Ticker Symbol | MBOT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000883975 |
| CUSIP Number | 59503A204 |
| ISIN Number | US59503A2042 |
| Employer ID | 94-3078125 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Harel Gadot | Co-Founder, President, Chief Executive Officer and Chairman |
| Yoseph Bornstein | Co-Founder and Independent Director |
| Rachel Vaknin | Chief Financial Officer |
| Dr. Simon Sharon MBA, MSc | Chief Technology Officer and GM of Microbot Israel |
| Dr. Juan Diaz-Cartelle | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 8-K | Current Report |
| Jul 1, 2024 | 424B5 | Filing |
| Jun 21, 2024 | EFFECT | Notice of Effectiveness |
| Jun 20, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 20, 2024 | D | Notice of Exempt Offering of Securities |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 11, 2024 | POS AM | Post-Effective amendments for registration statement |
| Jun 11, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 4, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 424B5 | Filing |